Introduction
============

More than 210 *Human papillomavirus* (HPV) genotypes have been detected so far. Adequate documents show that there is a relationship between HPV and some human cancers such as cervix cancer, head and neck carcinoma, penile cancer, oropharyngeal squamous cell carcinomas and, anal cancers ([@B1], [@B2]). According to the most recent meta-analysis study conducted on Iranian healthy female and female subjects with cervical cancer, the prevalence of HPV infection was 9.4% and 77.4%, respectively. The predominant genotype in both groups was HPV-16 ([@B3], [@B4]). Based on an estimated worldwide study published by the international agency for research on cancer (IARC), the HPV prevalence in female subjects with normal cytology in Africa, Latin America, Northern America, Asia, and Europe was 22.9%, 18.6%, 13.8%, 8.3%, and 6.6%, respectively and in a descending order ([@B5]). In less developed countries, cervix cancer is the second most common cancer ([@B5]) caused mostly by HPV-16 and -18 ([@B6]); however, cervical cancer is the 12^th^ most common cancer among Iranian female subjects ([@B7]). In male subjects, HPV-16 is the most frequent HPV genotype detected in penile cancer, and HPV-6 and -11 are often seen in genital warts ([@B8]). Although few studies have been carried out on HPV genotype distribution in Iranian male subjects, a recent study reported the 55.7% prevalence of HPV with HPV-6 as the most frequent genotype ([@B9]). HPV is an important agent in sexually transmitted diseases; screening and HPV genotyping tests, especially in low and middle income countries where HPV vaccination programs are not established, may help to improve the public health and prevent the spread of HPV infection ([@B10]). Even though Gardasil 4-valent is available in Iran, no national program exists to administer the vaccine to girls and boys.

The main objective of this study was to evaluate the distribution of HPV genotypes among Iranian males and females and provide a perspective of the dominant genotypes in the country. Although different studies on female or male samples have been accomplished in various provinces of Iran, as far the researchers investigated, this study is the first survey in Iran with a large sample size and participation of both male and female subjects. The findings might be helpful not only for setting future investigations and an agenda for public health, but also for vaccine development and national vaccination planning.

Materials and Methods
=====================

Procedure

In this cross-sectional study, a total of 8,351 (81.3%) females and 1,915 (18.7%) males from different provinces of Iran who were referred to Keyvan Laboratory of Tehran for HPV DNA testing and genotyping between April 2011 and April 2016 were enrolled. Almost all subjects were sexually active with an age range from 13 to 74 years old. The HPV DNA testing and genotyping were ordered by clinicians. Male samples were collected from anal and penile biopsies and female samples from the vagina and cervix through the use of either Dacron swabs or brush.

For DNA extraction, QIAamp DNA Mini kit (Qiagen GmbH, Germany) was utilized in accordance with the manufacturer's directions and the concentration of extracted DNA was evaluated by spectrophotometry in 260 nm. Genomic DNA of the samples was used in PCR using the MY09 and MY11 primers. DNA quality in samples was verified using beta-globin PCR assay.

Detection of HPV DNA and genotypes were carried out using INNO-LiPA assay (Fujirebio Europe N. V., Belgium). The INNO-LiPA HPV genotyping is based on the principle of reverse hybridization. Briefly, a part of L1 region called SPF10 of HPV genome was extended by specific primers; then, the biotinylated amplimers were denatured and hybridized with specific oligonucleotide probes. Furthermore, a primer pair of the human HLA-DPB1 gene was added to confirm the quality and extraction of DNA. Next, streptavidin-conjugated alkaline phosphatase was added. After incubation with BCIP/NBT chromogen, the results were interpreted visually.

Statistical analysis

IBM SPSS statistics version 22 ([@B11]) was used for statistical analysis as follows: 95% CI for prevalence estimations and the relation of HPV infection with age was performed using the Kruskal-Wallis test. A P-value less than 0.05 was considered to be statistically significant.

Results
=======

INNO LiPA HPV genotyping determined 32 HPV genotypes; HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, and -68 as high risk HPV genotypes (HR HPV), HPV-26, -53, -66, -70, -73, and -82 as possible high risk HPV genotypes (pHR HPV), and HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -67, -81, -83, and -89 as low risk HPV genotypes (LR HPV). This HPV classification was based on IARC Monographs (12). During the study period, the total HPV prevalence was 49.5%; hence, among 10,266 participants, 49.5% (n=5085) were HPV DNA positive and 50.5% (n=5181) were negative. [Figure (1)](#F1){ref-type="fig"} displays the overall HPV prevalence according to sex. HPV DNA was not detected in 44.0% (n=4510) of females and 6.5% (n=671) of males while HPV was genotyped in 37.4% (n=3841) of female subjects and 12.1% (n=1244) of male subjects.

Totally, among 5,085 samples from 31 Iranian provinces, four most common HPV genotypes were HPV-6, -11, -16, and -52 in male subjects and HPV-6, -16, -11, and -52/-53 (HPV-52 and HPV-53 were equal in frequencies) in female subjects, in a descending order. Among HR and pHR HPV genotypes, after HPV-52/-53 (9.6%), HR HPV-51 (8.0%) had the highest frequency in female subjects and also other genotypes with prevalence less than 8% included pHR HPV-66 (7.7%) and HR HPV-31 (7.0%). In male subjects, HR HPV-51 (2.8%) was the third most common HR HPV genotypes. The common HPV genotypes was observed in both single and mixed HPV infections and the genotypes which had high rates in the single HPV infection were also frequent in the mixed infections ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Tehran accounted for the most HPV DNA positive patients (40.1%) followed by Gilan (16.1%) and Mazandaran (5.6%) ([Table 3](#T3){ref-type="table"}).

![The percentage of HPV prevalence in the population (n=10266) of this study. HPV DNA was not detected in 44.0% and 6.5% of females and males, respectively; however, 37.4% of female subjects and 12.1% of male subjects were positive for HPV DNA](ijp-14-197-g001){#F1}

###### 

The prevalence of HPV genotypes as a single infection in Iranian female and male population

  Sex                                                                         
  ---------------------- ------ ------------------ ------ ------------------- -------------
  **%, 95% CI**          No     %, 95% CI          No     HPV Genotypes       
  **66.5 (64.0-68.9)**   828    26.1 (24.8-27.6)   1004   6                   **LR HPV**
  **10.5 (8.8-12.1)**    131    5.2 (4.5-6.0)      201    11                  
  **1.4 (0.8-2.2)**      18     0.7 (0.4-0.9)      26     44                  
  **0.2 (0.0-0.6)**      3      1.1 (0.8-1.4)      42     54                  
  **0.2 (0.0-0.4)**      2      0.7 (0.4-0.9)      26     62                  
  **0 (0.0-0.0)**        0      0.5 (0.3-0.8)      20     89                  
  **0 (0.0-0.0)**        0      0.2 (0.1-0.4)      9      43                  
  **0 (0.0-0.0)**        0      0.2 (0.1-0.4)      9      40                  
  **0 (0.0-0.0)**        0      0.4 (0.3-0.7)      17     61                  
  **0 (0.0-0.0)**        0      0.2 (0.1-0.4)      9      67                  
  **0 (0.0-0.0)**        0      0.3 (0.1-0.4)      10     81                  
  **0 (0.0-0.0)**        0      0.2 (0.1-0.4)      8      83                  
  **0.2 (0.0-0.6)**      3      0.3 (0.1-0.4)      10     42                  
  **0.2 (0.0-0.6)**      3      2.8 (2.3-3.4)      108    53                  **pHR HPV**
  **0.5 (0.2-0.9)**      6      1.7 (1.3-2.1)      65     66                  
  **0 (0.0-0.0)**        0      0.3 (0.1-0.4)      10     26                  
  **0.1 (0.0-0.2)**      1      0.3 (0.2-0.5)      12     73                  
  **0.1 (0.0-0.2)**      1      0.3 (0.1-0.5)      12     82                  
  **0.1 (0.0-0.2)**      1      0.2 (0.1-0.3)      6      70                  
  **2.7 (1.8-3.6)**      34     5.6 (4.8-6.2)      214    16                  **HR HPV**
  **0.2 (0.0-0.6)**      3      0.9 (0.7-1.2)      35     18                  
  **0.2 (0.0-0.4)**      2      0.6 (0.4-0.8)      23     31                  
  **0.1 (0.0-0.2)**      1      0.5 (0.3-0.7)      19     35                  
  **0.2 (0.0-0.6)**      3      1.2 (0.8-1.5)      45     39                  
  **0.1 (0.0-0.2)**      1      0.6 (0.4-0.9)      24     45                  
  **0.9 (0.4-1.4)**      11     1.9 (1.5-2.3)      72     51                  
  **0.6 (0.2-1.1)**      8      2.2 (1.8-2.7)      86     52                  
  **0.4 (0.1-0.7)**      4      0.9 (0.6-1.2)      33     56                  
  **0.1 (0.0-0.3)**      1      0.7 (0.5-1.0)      28     58                  
  **0.1 (0.0-0.2)**      1      0.5 (0.3-0.8)      21     68                  
  **0.2 (0.0-0.6)**      3      0.3 (0.1-0.4)      10     59                  
  **0.1 (0.0-0.3)**      1      0.2 (0.1-0.3)      7      33                  
  **14.1 (12.4-15.7)**   174    42.1 (40.2-43.9)   1620   Mixed infection\*   
  **100.0**              1244   100.0              3841                       **Total**

###### 

The prevalence of HPV genotypes in mixed infections in Iranian female and male population

  HPV genotypes                      Females   Males                    
  ---------------------------------- --------- ------------------ ----- ------------------
  HPV-6                              659       40.7 (38.2-43.0)   139   79.9 (73.6-85.6)
  HPV-11                             236       14.6 (13.0-16.5)   40    23.0 (16.7-29.3)
  HPV-16                             426       26.3 (24.3-28.6)   34    19.5 (13.8-25.9)
  HPV-52                             282       17.4 (15.6-19.2)   32    18.4 (12.7-24.1)
  HPV-53                             259       16.0 (14.2-17.8)   15    8.6 (4.6-13.2)
  HPV-31                             247       15.2 (13.5-17.1)   13    7.5 (4.0-12.1)
  HPV-51                             236       14.6 (13.0-16.5)   24    13.8 (9.2-19.0)
  HPV-66                             232       14.3 (12.7-16.1)   16    9.2 (5.2-13.8)
  HPV-39                             178       11.0 (9.4-12.5)    9     5.2 (2.3-8.6)
  HPV-18                             143       8.8 (7.3-10.3)     11    6.3 (2.9-10.3)
  HPV-45                             84        5.2 (4.2-6.4)      2     1.1 (0.0-2.9)
  Total number of mixed infections   1620                         174   

###### 

The frequency and percentage of HPV infections of 31 Iranian provinces among HPV DNA samples

  Province                         Frequency   %\*, 95% CI
  -------------------------------- ----------- ------------------
  Alborz                           296         5.8 (5.2-6.5)
  Ardabil                          80          1.6 (1.2-1.9)
  Bushehr                          45          0.9 (0.6-1.1)
  Chaharmahal and Bakhtiari        31          0.6 (0.4-0.8)
  East Azerbaijan                  68          1.3 (1.0-1.7)
  Esfahan                          72          1.4 (1.1-1.8)
  Fars                             67          1.3 (1.0-1.7)
  Gilan                            817         16.1 (15.0-17.1)
  Golestan                         23          0.5 (0.3-0.6)
  Hamadan                          11          0.2 (0.1-0.4)
  Hormozgan                        115         2.3 (1.9-2.7)
  Ilam                             2           0.0 (0.0-0.1)
  Kerman                           35          0.7 (0.5-0.9)
  Kermanshah                       61          1.2 (0.9-1.5)
  Khuzestan                        165         3.2 (2.8-3.8)
  Kohgiluyeh and Boyer-Ahmad       5           0.1 (0.0-0.2)
  Kurdistan                        68          1.3 (1.0-1.7)
  Lorestan                         69          1.4 (1.0-1.7)
  Markazi                          139         2.7 (2.3-3.2)
  Mazandaran                       286         5.6 (5.0-6.3)
  Northern Khorasan (Bojnord)      62          1.2 (0.9-1.5)
  Qazvin                           55          1.1 (0.8-1.4)
  Qom                              203         4.0 (3.5-4.6)
  Razavi Khorasan (Mashhad)        43          0.8 (0.6-1.1)
  Semnan                           25          0.5 (0.3-0.7)
  Sistan and Baluchestan (Zabol)   40          0.8 (0.6-1.0)
  South Khorasan (Birjand)         11          0.2 (0.1-0.4)
  Tehran                           2073        40.8 (39.4-42.1)
  West Azerbaijan                  58          1.1 (0.9-1.5)
  Yazd                             48          0.9 (0.7-1.2)
  Zanjan                           12          0.2 (0.1-0.4)
  Total                            5085        100.0

Overall, the mixed HPV infections were found in 14.0% (n=174) of HPV DNA positive males, while 42.2% (n=1620) of HPV infection in females were caused by mixed HPV genotypes. Concomitant infection with at least two LR HPV genotypes was detected in 3.3% (168/5085) of all positive cases. In both sexes with mixed HPV genotypes, concurrent infection by at least one HR and one LR HPV genotype was commonly observed than other forms of mixed infections ([Table 2](#T2){ref-type="table"}). Only 0.3% (n=11) of females had pHR HPV genotypes as the mixed infection, and no similar cases were not found in males ([Table 4](#T4){ref-type="table"}).

A total of 5,085 samples which were positive for HPV DNA were selected for more statistical analysis. They were divided into 4 age groups: 13-29, 30-44, 45-59, and 60-74 years ([Table 5](#T5){ref-type="table"}). In our study, like other studies ([@B9], [@B13]) no statistically significant correlation was found between HPV infection and age (*P*=1); however, 90.6% and 86.4% of the HPV infections in female and male subjects were seen in subjects aged 13 to 44 years, respectively. The highest rate of HPV infection occurred in positive subjects aged 30-44 years ([Table 5](#T5){ref-type="table"}). [Figure (2)](#F2){ref-type="fig"} shows an upward trend of the frequency of HPV infection by age increasing with a peak at 30 and 32 years in both sexes. Along with age increasing, the rate of infection by HPV declines steadily and the lowest rate is seen in the age range 60-74 years.

Distribution of HPV genotypes based on age groups was different in both sexes. In female subjects, HPV-16, as the most HR HPV genotypes, was more observed in the age group 30-44 years. The second and third common HPV genotypes were HPV-53 and HPV-52, which were detected more frequently in the age group 30-44 years. Interestingly, these three genotypes were not found in female subjects older than 60 years old. HPV-6, as commonly detected LR HPV genotypes, was almost equal in two age groups (13-29 and 30-45 years). In male subjects, the subjects aged 30-44 years had the first and second most frequent HR HPV and LR HPV genotypes: HR HPV-16, -51/-52 (the frequencies of HPV-52 and HPV-53 were equal), and LR HPV-6, -11. In the participants \>60 years of age, HPV-6 and -11 were the most detectable HPV genotypes (data not shown). [Table 6](#T6){ref-type="table"} shows HPV prevalence and three common genotypes of noncancerous cervical samples in Iran's neighbouring countries.

![The frequency of HPV infection according to the age in the studied males and females](ijp-14-197-g002){#F2}

###### 

The prevalence of HPV genotypes in the mixed infections\*

                                Female   Male                     
  ----------------------------- -------- ------------------ ----- ------------------
                                No       %\*\*, 95% CI      No    %\*\*, 95% CI
  LR HPV genotypes              139      3.6 (3.1-4.2)      29    2.3 (1.5-2.3)
  HR or/and pHR HPV genotypes   487      12.7 (11.6-13.8)   16    1.3 (0.7-2.0)
  HR and LR HPV genotypes       994      26.0 (24.5-27.2)   129   10.4 (8.7-12.2)
  Total                         1620     42.2 (40.6-43.7)   174   14.0 (12.1-15.8)

###### 

Distribution of HPV genotypes by age groups and sex

  HPV genotypes       Sex                  13-29 y       30-44 y       45-59 y     60-74 y    **Total**
  ------------------- -------- ----------- ------------- ------------- ----------- ---------- ----------------
  LR HPVs             F        No (%)\*    630 (12.4)    738 (14.5)    142 (2.8)   11 (0.2)   
  M                   No (%)   277 (5.4)   591 (11.6)    128 (2.5)     19 (0.4)               
  HRor/and pHR HPVs   F        No (%)      493 (9.7)     715 (14.1)    100 (2.0)   16 (0.3)   
  M                   No (%)   35 (0.7)    55 (1.1)      9 (0.2)       1 (0.0)                
  HR and LR HPVs      F        No (%)      454 (8.9)     452 (8.9)     86 (1.7)    4 (0.1)    
  M                   No (%)   35 (0.7)    82 (1.6)      11 (0.2)      1 (0.0)                
  Total                        No (%)      1924 (37.8)   2633 (51.8)   476 (9.4)   52 (1.0)   **5085 (100)**

###### 

HPV prevalence and three common genotypes of noncancerous cervical samples in Iran's neighbouring countries

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                      HPV prevalence in healthy female subjects\*\*\          Three common genotypes   HPV genotyping assay                                      Reference
                               (Type of patients)                                                                                                                         
  ---------------------------- ------------------------------------------------------- ------------------------ --------------------------------------------------------- -----------
  Turkey                       17.9%\                                                  HPV-16 (3.6%),           line blot assay                                           ([@B30])
                               (patients with normal pap smear)                                                                                                           

  HPV-6 (2.6%),                                                                                                                                                           

  HPV-45 (2.2%)                                                                                                                                                           

  Pakistan\                    4.74%\                                                  HPV-6 (25%),             the partial HPV L1 region sequencing                      ([@B31])
  **(Punjab)**                 (patients with normal cervical cytology)                                                                                                   

  HPV-55 (22.9%),                                                                                                                                                         

  HPV-11 (20.8%)                                                                                                                                                          

  Qatar                        7.6%\                                                   HPV-81 (34.5%),          real-time PCR and Sanger sequencing                       ([@B32])
                               (patients with normal and abnormal cervical cytology)                                                                                      

  HPV-11 (31.0%),                                                                                                                                                         

  HPV-35 (6.9%)                                                                                                                                                           

  Iraq (Kurdistan Region)      12.5% (Patients with vaginal discharge)                 HPV-16 (53.8%)           Conventional PCR                                          ([@B33])

  Kuwait                       2.4%\                                                   HPV-11 (22.5%),          PCR-based sequencing                                      ([@B34])
                               (patients with normal cervical cytology)                                                                                                   

  HPV-81 (18.3%),                                                                                                                                                         

  HPV-61 (12.6%),                                                                                                                                                         

  **The Kingdom of Bahrain**   9.8%\                                                   HPV-52 (1.4%),           PCR DNA enzyme immunoassay (PCR-DEIA) and LiPA25 system   ([@B35])
                               (patients with normal pap smear)                                                                                                           

  HPV-16 (1.1%)                                                                                                                                                           

  HPV-31 (1.1%)                                                                                                                                                           

  HPV-51 (1.1%)                                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

HPV distribution varies in different countries and populations and even though in various parts of a country. For example, HPV-16 in Zhejiang province, HPV-52 in Guiyang and Guangdong provinces, and HPV-6 in Xi\'an province of China are predominant genotypes ([@B14], [@B15]). In this study, we examined 10,266 Iranian male and female subjects with normal pap-smear, cell collections from vagina, cervix, and bulge of penile and anal sites of males from 31 provinces which showed an overall HPV prevalence of 49.5%. Based on a global study on female subjects with normal pap-smear, this rate of HPV prevalence was much higher than both neighboring countries and other regions in the world. The highest burden of HPV infection was estimated in African and Latin American countries and the lowest in southern Europe and South East Asia ([@B12]). No fixed pattern of the HPV genotypes distribution observed even in different parts of a province, e,g, the samples from suburb of Tehran commonly demonstrated mixed infections (the data were not shown). Although no sociodemographic data are available, low education and inappropriate economic conditions may be an explanation, high risk HPV distribution is affected by sexual behavior, host immune factors, environmental factors, smoking, having multiple sex partners, and the presence of other sexually transmitted infections ([@B16]). Therefore, HPV as an important transmitted infection causes some critical HPV-associated cancers in human, circulating HPV genotypes should be available to plan better the prevention. In different studies done on routine pap-smear samples in Iran, HPV-16 and -18 represented as the main genotypes ([@B13], [@B17], [@B18]), which are in disagreement with our results, as HPV-18 contained 9^th^ or higher in our study. Vaccinated female may reduce the HPV infections in male subjects, due to herd immunity ([@B19]); hence, domination of HPV-6, -11, -16, and -52 in female subjects of this study may explain the prevalence of these HPV genotypes in male subjects or vice versa. [Table (6)](#T6){ref-type="table"} displays the overall HPV genotypes prevalence and three frequent HPV genotypes in female subjects of Iran's neighboring countries. Not only no common distribution pattern was observed between Iran and its neighbors, but also our findings are in contradiction with previous surveys conducted in Iran. In addition, in Saudi Arabia, as a country which Iranian people travel annually for pilgrimage, HPV-16, -18, and -11 were reported as three common genotypes ([@B20]). According to the latest report, cervical cancer is the 12^th^ most common cancer among Iranian female ([@B7]). On the one hand, based on our findings, the major genotype circulating in the normal population is HPV-6, which may justify the reduction of cervix cancer in the country. On the other hand, HPV-16 as the most important HR HPV genotype in the studied population and cancerous samples ([@B3]) has generally four lineages (A-D) that non-European variants (B-D) ([@B21]) play a key role in the development of an invasive form of cervical cancer ([@B22]). D is the prevalent lineage in Iranian females ([@B23]). Therefore, the importance of vaccination is well perceptible. In addition, there are no regular cervical cancer screening, either vaccination program or a national cancer registry. This study, in line with other previous studies, recommends to set up serious hygiene policies in case of HPV infections.

Men with HPV infection only accounted for 12.1% of all HPV DNA cases. Among this, 86.0% had a single infection. The predominant three HPV genotypes found were in complete agreement with those were reported by Salehi-Vaziri in 2015 ([@B9]). Only almost one-seventh of male subjects were positive for mixed infections compared to the female subjectss where less than half of them were infected with mixed HPV genotypes. In Iran, nearly all boys are circumcised before the age of seven because of religious beliefs. Based on two meta-analysis studies, although no association was observed between HPV clearance and HPV acquisition of new infections, there was a significant reduction in genital HPV infection prevalence in male circumcision (OR=0.57) ([@B24], [@B25]), which may be a possible reason in the reduction of HPV infections or mixed infections in male subjects of this study.

The age distribution of HPV infection in both sexes showed a mono summit graph with a peak age of 30-32 years. There was the highest incidence in the age of marriage and after beginning of the sexual activity due to some cultural habits, religious beliefs such as not to have illegitimate sex, increasing the age of marriage, and absence of immune protection against HPV in the lack of national vaccination program. Also, the rate of mixed infections is increased with the rise in the frequency of sexual contact and high-risk sexual behaviour ([@B26]). The steady decrease in the HPV infection rate in the middle age and elder individuals might explain the present immunity due to the natural history of HPV infection or self-limiting HPV infection within 18 months after infection as a result of host immune responses ([@B15], [@B27]). Although we had no information about the sexual activity of the participants or the status of HPV infection in parents of the children, self- or hetero-inoculation, the route of spreading of LR HPV infections in young people who have no sexual experiences, may justify the presence of HPV genotypes in the adolescents. ([@B28], [@B29]).

An important limitation of this study was the lack of cytology information of positive samples for correlation with the results of HPV genotypes. Another limitation, this rate of HPV prevalence may not reflect the distribution of HPV genotypes in the country since this study recruited only the samples with normal pap-smear, cell collections from vagina, and cervix in female subjects, and bulge of penile and anal sites in male subjects. Hence, similar studies need to be conducted on cancerous samples. No demographic data of participants such as marital status, job, and the number of sex partners were available. In spite of the male subjects' limitations, this study gives an insight into the present status of the distribution of HPV genotypes in the target population and is helpful for setting policies.
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